Immunological therapies can relieve aromatase inhibitor-related joint symptoms in breast cancer survivors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 6, 2010, Pages 557-560

  Zhang, Qingyuan ^a   Tang, Dabei ^a   Zhao, Hong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cytokines; Immunologic therapies; Joint symptoms; Thymosin 1

Indexed keywords

ANASTROZOLE; EXEMESTANE; GAMMA INTERFERON; INTERLEUKIN 4; LETROZOLE; THYMOSIN ALPHA1;

ADULT; AGED; ARTHROPATHY; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER STAGING; CANCER SURVIVOR; CLINICAL ARTICLE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; OSTEOARTHRITIS; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; WELLBEING;

AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; PAIN MEASUREMENT; PATIENT SATISFACTION; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; SURVIVORS; THYMOSIN; TREATMENT OUTCOME;

EID: 78650004181     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181cae782     Document Type: Article

References (25)

1. Thurlimann B. Hormonal treatment of breast cancer: new developments. Oncology. 1998;55:501-507.
2. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early stage breast cancer. J Clin Oncol. 2008;26:556-562.
3. Yamamoto Y, Iwase H. Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. Int J Clin Oncol. 2008;13:384-394.
4. Goss PE, Hadji P, Subar M, et al. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res. 2007;9:R52.
5. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early stage breast cancer. J Clin Oncol. 2007;25:3877-3883.
6. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005;52:2594-2598.
7. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25:3797-3799.
8. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16:223-234.
9. Benoit M, Hubert M, Pierre M. Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis. 2007;66:557-558.
10. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol. 2007;14(suppl 1):S11-S19.
11. Swaak AJ, van den Brink HG, Aarden LA. Cytokine production in whole blood cell cultures of patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56:693-695.
12. Chen PF, Zhang HY, Fu GF, et al. Overexpression of soluble human thymosin alpha 1 in Escherichia coli. Acta Biochim Biophys Sin (Shanghai). 2005;37:147-151.
13. Bodey B. Thymic hormones in cancer diagnostics and treatment. Expert Opin Biol Ther. 2001;1:93-107.
14. Hannappel E, Huff T. The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function. Vitam Horm. 2003;66:257-296.
15. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23:129-138.
16. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
17. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15:974-986. (Pubitemid 27106280)
18. Castel LD, Abernethy AP, Li Y, et al. Hazards for pain severity and pain interference with daily living, with exploration of brief pain inventory cutpoints, among women with metastatic breast cancer. J Pain Symptom Manage. 2007;34:380-392.
19. Bellamy N, Campbell J, Hill J, et al. A comparative study of telephone versus onsite completion of the WOMAC 3.0 osteoarthritis index. J Rheumatol. 2002;29:783-786.
20. Dapueto JJ, Francolino C, Servente L, et al. Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish version 4 in South America: classic psychometric and item response theory analyses. Health Qual Life Outcomes. 2003;1:32.
21. SAVAGE O. Arthritis and rheumatism at the menopause. Practitioner. 1959;182:570-573.
22. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100: 1581-1591.
23. Shim GJ, Warner M, Kim HJ, Andersson S, et al. Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci U S A. 2004;101: 12628-12633.
24. Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest. 2004;114:471-474.
25. Seitz M, Napierski I, Augustin R, et al. Reduced production of interferon alpha and interferon gamma in leukocyte cultures from patients with active rheumatoid arthritis. Scand J Rheumatol. 1987;16:257-262.